Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors.

Melanoma is a cancer with a high incidence rate that, despite the significant development of therapeutic options, still remains a major problem. The identification of biomarkers to select the right therapy for the right patient is one of the possibilities to improve the prognosis of patients. Potentially, the function of biomarkers could be played long non-coding RNAs (lncRNAs). The expression of selected 90 lncRNAs in serum from 30 metastatic melanoma patients with confirmed mutations in the BRAF V600 E or K gene was studied. Serum was collected prior to BRAF and MEK inhibitor therapy. The control group consisted of 16 healthy volunteers. A total of 41 lncRNAs were identified the expression of which differed statistically significantly between the patient group and the healthy volunteers. In addition, it was shown that the expression of HOXA3as (

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lukasz Galus reports a relationship with 10.13039/100002491Bristol-Myers Squibb Co that includes: speaking and lecture fees and travel reimbursement. Jacek Mackiewicz reports a relationship with 10.13039/100002491Bristol-Myers Squibb Co that includes: speaking and lecture fees and travel reimbursement. Jacek Mackiewicz reports a relationship with 10.13039/100004334Merck & Co Inc that includes: speaking and lecture fees and travel reimbursement. Lukasz Galus reports a relationship with 10.13039/100013226Pierre Fabre SA that includes: speaking and lecture fees and travel reimbursement. Jacek Mackiewicz reports a relationship with 10.13039/100013226Pierre Fabre SA that includes: speaking and lecture fees and travel reimbursement. Lukasz Galus reports a relationship with 10.13039/100008272Novartis Pharmaceuticals Corporation that includes: speaking and lecture fees and travel reimbursement. Jacek Mackiewicz reports a relationship with 10.13039/100008272Novartis Pharmaceuticals Corporation that includes: speaking and lecture fees and travel reimbursement. Lukasz Galus reports a relationship with 10.13039/100004334Merck & Co Inc that includes: speaking and lecture fees and travel reimbursement. Jacek Mackiewicz reports a relationship with 10.13039/100004337Roche that includes: speaking and lecture fees and travel reimbursement. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.